Healthcare Private Placement and M&A Transactions Review Week Ending October 6, 2024

Aktis Oncology: The company raised $175 million of Series B venture funding in a deal led by RA Capital Management, RTW Investments and Janus Henderson Investors on September 30, 2024. MRL Ventures Fund, Eli Lilly and Company, Avidity Partners, and Bristol-Myers Squibb Foundation also participated in the round. The company is a developer of a targeted radiopharmaceutical designed to treat a broad range of solid tumor cancers.

Nusano: The company closed on an estimated $115 million of an undisclosed targeted amount of Series C venture funding in a deal led by Wasatch Group in October 2024. S32 and other undisclosed investors also participated in the round. The company is an operator of a biotech business focused on uranium-free radioisotope development and production in various diagnostic and therapeutic medical applications.

Resolution Therapeutics: The company raised GBP 63.5 million of Series B venture funding in a deal led by Syncona on October 3, 2024. The company is a developer of cell therapies designed to aid in the treatment of end-stage liver diseases.

LoQus23 Therapeutics: The company raised GBP 35 million of Series A venture funding in a deal led by Forbion on October 2, 2024. Novartis Venture Fund and SV Health Investors also participated in the round. The company is an operator of a biotechnology business intended to develop small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease.

VieCure: The company raised $45 million of venture funding from Northpond Ventures on September 30, 2024. The company is an operator of an AI-powered comprehensive cancer care platform.

Arda Therapeutics: The company raised $43.3 million of Series A venture funding from Andreessen Horowitz on October 1, 2024, putting the company’s pre-money valuation at $36.7 million. The company is a developer of therapeutics designed to remove pathological cells which are the root causes of chronic diseases and aging.

C2N Diagnostics: The company raised $40 million of venture funding from Eisai, Alzheimers Drug Discovery Foundation and GHR Foundation on September 30, 2024. Diagnostics Accelerator also participated in the round. The company is an operator of a molecular diagnostics business aiming to transform the early diagnosis and early treatment of Alzheimer’s disease and related forms of neurodegeneration.

ShiraTronics: The company raised $37.4 million of venture funding from undisclosed investors on September 30, 2024. The company is a developer of novel neuromodulation technologies designed to treat unmet neurology-based clinical needs.

Enara Bio: The company raised $32.5 million of Series B venture funding in a deal led by Pfizer Ventures and M Ventures on October 3, 2024. SV Health Investors, RA Capital Management, Samsara BioCapital, and The Francis Crick Institute also participated in the round. The company is a developer of medical drug vaccines and other immunotherapies designed to treat cancer.

Mindpeak: The company raised EUR 15.3 million of Series A venture funding in a deal led by Innovationsstarter and ZEISS Ventures on September 30, 2024. European Innovation Council Fund and AI.Fund also participated in the round. The company is a developer of an artificial intelligence-based visual diagnosis platform designed to increase microscopical analysis access.

Hyalex Orthopaedics: The company raised $14.9 million of Series B venture funding from undisclosed investors on October 2, 2024, putting the company’s pre-money valuation at $54 million. The company is a developer of a biomimetic material designed to simulate cartilages for diseased and damaged joints.

Emit Imaging: The company raised $5.85 million of venture funding from undisclosed investors on October 3, 2024. The company is a developer of an imaging technology designed to monitor drug distribution and protein expression.

ThoroughCare: The company raised $5 million of Series A-1 venture funding from undisclosed investors on October 2, 2024, putting the company’s pre-money valuation at $63 million. The company is an operator of a digital healthcare platform.

aitiologic: The company raised EUR 2.5 million of venture funding in a deal led by PUSH Ventures and LANA Ventures on October 1, 2024. AWS and Forschungsförderungsgesellschaft also participated in the round. The company is a developer of AI-powered precision medicine technology intended for early disease detection and targeted therapy.

CellVax Therapeutics: The company raised just over $2 million of venture funding from undisclosed investors on October 4, 2024. The company is a developer of cell-based immunotherapies designed to recognize abnormality of tumor cells.

Janus Health: The company raised $2 million of venture funding from undisclosed investors on October 4, 2024. The company is a developer of a SaaS-based workforce management and automation platform intended for healthcare revenue cycle management.

Peer: The company raised an undisclosed amount of venture funding from Shift Left Ventures in October 2024. The company is a developer of a medical writing tool designed to speed up drug development through data ingestion automation.

PYM: The company raised an undisclosed amount of venture funding from Flagstaff Ventures in October 2024. The company is a manufacturer of all-natural, amino acid-based chewable gums intended to improve neurotransmitter health.

Springbok Analytics: The company raised an undisclosed amount of venture funding from Cartan Capital in October 2024. The company is a developer of a muscle analytics platform designed to transform magnetic resonance images into holistic, interactive three-dimensional twins of an athlete’s exact musculature.

Tessel: The company raised an undisclosed amount of venture funding from Life Extension Ventures in October 2024. The company is an operator of an AI-enabled pharmaceutical development business which uses a high-throughput discovery platform to model chronic diseases.

Genentech / Lonza Group: The Biologics Manufacturing Unit of Genentech was acquired by Lonza Group for $1.2 billion on October 2, 2024. The company is a manufacturer of biotechnology products based in Vacaville, California.

Seres Therapeutics / Nestlé Health Science: The VOWST Business of Seres Therapeutics was acquired by Nestlé Health Science, a subsidiary of Nestlé, for $525 million on September 30, 2024. The company is a developer of microbiome therapeutics intended to prevent the recurrence of Clostridioides difficile infection.

OnKure Therapeutics / Reneo Pharmaceuticals: The company acquired Reneo Pharmaceuticals through a reverse merger for an estimated $65 million, resulting in the combined entity trading on the NASDAQ stock exchange under the ticker symbol OKUR on October 4, 2024. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers that are underserved by available therapies.

Bioness / Accelmed: The company, a subsidiary of Bioventus, entered into a definitive agreement to be acquired by Accelmed through a $45 million LBO on October 1, 2024. The company is a developer of non-invasive medical devices intended to help individuals with neurological impairments.

Cathtek / Eimo Technologies: The company was acquired by Eimo Technologies for $18 million on October 1, 2024. The company is a manufacturer of disposable medical devices intended to provide products for various diagnostic and testing applications.

Dynamic Biosensors / Bruker: The company was acquired by Bruker for an undisclosed amount on October 2, 2024. The company develops and markets innovative technologies for studying complex molecular interactions and kinetics which supports drug discovery in the pharma and biotech industries.

Emglev Therapeutics / Valerio Therapeutics: The company was acquired by Valerio Therapeutics for an undisclosed amount on September 29, 2024. The company is a developer of antibody treatments designed for diseases, cancers, and solid tumors.

Scalabull / RXNT: The company was acquired by RXNT for an undisclosed amount on October 2, 2024. The company connects Electronic Health Record vendors with diagnostic service providers through a nationwide network of clinical laboratories and radiology facilities.

Serelys / UPSA: The company was acquired by UPSA, a subsidiary of Taisho Pharmaceutical Holdings, for an undisclosed amount on October 1, 2024. The company is an operator of a pharmaceutical business intended to offer food supplements.

SkinCure Oncology / H.I.G. Capital: The company was acquired by H.I.G. Capital through an LBO on October 1, 2024 for an undisclosed amount. The company is a developer of a skin cancer treatment technology intended to provide a non-invasive alternative for the treatment of non-melanoma skin cancer.

Vertos Medical / Stryker: The company was acquired by Stryker for an undisclosed amount on October 1, 2024. The company is a developer of minimally invasive medical devices designed to assist in the treatment of common spinal diseases.

VisiQuate / Accel-KKR: The company was acquired by Accel-KKR through an LBO on October 1, 2024 for an undisclosed amount. The company is a developer of revenue cycle management and analytics software designed to provide enhanced financial, operational and clinical outcomes.